Interaction Checker

Avanafil : interactions médicamenteuses

Avanafil (Stendra), inhibiteur de la PDE5, présente 162 interactions documentées dans les notices FDA et les fiches d'information que nous indexons : 45 de niveau majeur, 117 de niveau modéré, 0 de niveau mineur et 0 cas où une notice ne signale aucune interaction significative. Chaque entrée ci-dessous cite la phrase sur laquelle elle repose. Cette page consacrée à un médicament est un point de départ, pas un verdict sur votre situation.

À quoi ressemble Avanafil

Voir les 6 versions
Avanafil 100 mg en comprimé : jaune, ovale, 9 mm, inscription 100mg.
100mg
100 mg · jaune · ovale · 9 mm
Metuchen
Avanafil 200 mg en comprimé : jaune, ovale, 12 mm, inscription 200mg.
200mg
200 mg · jaune · ovale · 12 mm
Metuchen
Avanafil 50 mg en comprimé : jaune, ovale, 7 mm, inscription 50mg.
50mg
50 mg · jaune · ovale · 7 mm
Metuchen
Avanafil 50 mg en comprimé : blanc, ovale, 7 mm, inscription A41 sur une face et H sur l'autre.
A41 / H
50 mg · blanc · ovale · 7 mm
Camber

Rendus réalisés à partir des fiches produit des notices FDA : couleur, forme, taille et inscription. 6 versions documentées chez 2 laboratoires.

Interactions d'après la notice

Interactions majeures (45)

  • AmiodaroneantiarythmiqueMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Aprépitantinhibiteur du CYP3A4Majeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • AtazanavirantirétroviralMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • CénobamateanticonvulsivantMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • CiclosporineimmunosuppresseurMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Cimétidineantihistaminique H2Majeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Clarithromycineantibiotique macrolideMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • DarunavirantirétroviralMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Darunavir et cobicistatantirétroviralMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Diltiazeminhibiteur calciqueMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Dinitrate d'isosorbidedérivé nitréMajeure

    • Administration of avanafil tablet to patients using any form of organic nitrate is contraindicated ( 4.1 ) (notice Avanafil, Contre-indications)

  • Dinitrate d'isosorbide et hydralazinedérivé nitréMajeure

    • Administration of avanafil tablet to patients using any form of organic nitrate is contraindicated ( 4.1 ) (notice Avanafil, Contre-indications)

  • DronédaroneantiarythmiqueMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • ÉfavirenzantirétroviralMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Éfavirenz, lamivudine et ténofovirantirétroviralMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Elvitégravir, cobicistat, emtricitabine et ténofovirantirétroviralMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Érythromycineantibiotique macrolideMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • ÉvérolimusimmunosuppresseurMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Fluconazoleantifongique azoléMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • FosamprénavirantirétroviralMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Fosaprépitantinhibiteur du CYP3A4Majeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Imatinibinhibiteur du CYP3A4Majeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • IsoniazideantibiotiqueMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Itraconazoleantifongique azoléMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Ivacaftorinhibiteur du CYP3A4Majeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Kétoconazoleantifongique azoléMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • LénacapavirantirétroviralMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Lopinavir et ritonavirantirétroviralMajeure

    Do not use avanafil in patients taking ritonavir. (notice Avanafil, Interactions médicamenteuses)

  • Mifépristoneinhibiteur du CYP3A4Majeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Mirabégronagoniste bêta-adrénergiqueMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Mononitrate d'isosorbidedérivé nitréMajeure

    • Administration of avanafil tablet to patients using any form of organic nitrate is contraindicated ( 4.1 ) (notice Avanafil, Contre-indications)

  • NéfazodoneantidépresseurMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Nirmatrelvir et ritonavirantiviralMajeure

    Do not use avanafil in patients taking ritonavir. (notice Avanafil, Interactions médicamenteuses)

  • Palbociclibinhibiteur du CYP3A4Majeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • PérampanelanticonvulsivantMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Posaconazoleantifongique azoléMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Ranolazinemédicament allongeant l'intervalle QTMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • RiociguatvasodilatateurMajeure

    • Administration with guanylate cyclase (GC) stimulators such as riociguat and vericiguat ( 4.3 ) (notice Avanafil, Contre-indications)

  • RitonavirantirétroviralMajeure

    Do not use avanafil in patients taking ritonavir. (notice Avanafil, Interactions médicamenteuses)

  • Suvorexantsédatif-hypnotiqueMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Ticagrélorantiagrégant plaquettaireMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • Trinitrinedérivé nitréMajeure

    • Administration of avanafil tablet to patients using any form of organic nitrate is contraindicated ( 4.1 ) (notice Avanafil, Contre-indications)

  • Vérapamilinhibiteur calciqueMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

  • VériciguatvasodilatateurMajeure

    • Administration with guanylate cyclase (GC) stimulators such as riociguat and vericiguat ( 4.3 ) (notice Avanafil, Contre-indications)

  • Voriconazoleantifongique azoléMajeure

    Do not use avanafil in patients taking strong CYP3A4 inhibitors [see Warnings and Precautions ( 5.2 ) and Dosage and Administration ( 2.3 )]. (notice Avanafil, Interactions médicamenteuses)

Interactions modérées (117)

  • AcébutololbêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Acide étacryniquediurétique de l'anseModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • AlcoolAlcoolModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • AlfuzosinealphabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • AliskirèneantihypertenseurModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Alprostadilanalogue de prostaglandineModérée

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (notice Avanafil, Mises en garde et précautions)

  • Amiloridediurétique épargneur de potassiumModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Amlodipineinhibiteur calcique dihydropyridiniqueModérée

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (notice Avanafil, Interactions médicamenteuses)

  • Amlodipine et atorvastatineinhibiteur calcique dihydropyridiniqueModérée

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (notice Avanafil, Interactions médicamenteuses)

  • Amlodipine et bénazéprilinhibiteur calcique dihydropyridiniqueModérée

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (notice Avanafil, Interactions médicamenteuses)

  • Amlodipine et olmésartaninhibiteur calcique dihydropyridiniqueModérée

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (notice Avanafil, Interactions médicamenteuses)

  • Amlodipine et valsartaninhibiteur calcique dihydropyridiniqueModérée

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (notice Avanafil, Interactions médicamenteuses)

  • AténololbêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Aténolol et chlortalidonebêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Azilsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Bénazéprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Bénazépril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • BétaxololbêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Bictégravir, emtricitabine et ténofovir alafénamideantirétroviralModérée

    PDE-5 inhibitors for erectile dysfunction (ED): Refer to the prescribing information of PDE-5 inhibitors for dose recommendations. (notice Bictégravir, emtricitabine et ténofovir alafénamide, Interactions médicamenteuses)

  • BisoprololbêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Bisoprolol et hydrochlorothiazidebêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Candésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Candésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Cannabidiol (sur ordonnance)anticonvulsivantModérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

  • CapécitabineantimétaboliteModérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

  • Captoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • CarvédilolbêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Chlorothiazidediurétique thiazidiqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Chlortalidonediurétique thiazidiqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Clonidineagoniste alpha-adrénergiqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Disulfirameinhibiteur du CYP2C9Modérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

  • DoxazosinealphabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Dutastéride et tamsulosineinhibiteur de la 5-alpha-réductaseModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Énalaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Énalapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Énalaprilateinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Éplérénoneantagoniste de l'aldostéroneModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Époprosténolanalogue de prostaglandineModérée

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (notice Avanafil, Mises en garde et précautions)

  • ÉtravirineantirétroviralModérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

  • Félodipineinhibiteur calcique dihydropyridiniqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • FluorouracileantimétaboliteModérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

  • FluvastatinestatineModérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

  • Fosinoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Fosinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Furosémidediurétique de l'anseModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Guanfacineagoniste alpha-adrénergiqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • HydralazinevasodilatateurModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Hydrochlorothiazidediurétique thiazidiqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Indapamidediurétique thiazidiqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Irbésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Irbésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Isradipineinhibiteur calcique dihydropyridiniqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • LabétalolbêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Lisinoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Lisinopril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Lofexidineagoniste alpha-adrénergiqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Losartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Losartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • MécamylamineantihypertenseurModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • MéthyldopaantihypertenseurModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Métolazonediurétique thiazidiqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • MétoprololbêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Métoprolol et hydrochlorothiazidebêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • MétronidazoleantibiotiqueModérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

  • Miconazoleantifongique azoléModérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

  • MinoxidilvasodilatateurModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Moexiprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • NadololbêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • NébivololbêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Nicardipineinhibiteur calcique dihydropyridiniqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Nifédipineinhibiteur calcique dihydropyridiniqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Nimodipineinhibiteur calcique dihydropyridiniqueModérée

    Blood Pressure Lowering Drugs Nimodipine may increase the blood pressure lowering effect of concomitantly administered anti-hypertensives such as diuretics, beta-blockers, ACE inhibitors, angiotensin receptor blockers, other calcium channel blockers, α-adrenergic blockers, PDE5 inhibitors, and α-methyldopa. (notice Nimodipine, Interactions médicamenteuses)

  • Nisoldipineinhibiteur calcique dihydropyridiniqueModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Nitisinoneinhibiteur du CYP2C9Modérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

  • Nitroprussiate de sodiumvasodilatateurModérée

    In vitro studies with human platelets indicate that avanafil potentiates the anti-aggregatory effect of sodium nitroprusside (a nitric oxide [NO] donor). (notice Avanafil, Mises en garde et précautions)

  • Olmésartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Olmésartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Olmésartan, amlodipine et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (notice Avanafil, Interactions médicamenteuses)

  • PamplemousseAliments et boissonsModérée

    Although specific interactions have not been studied, other CYP3A4 inhibitors, including grapefruit juice are likely to increase avanafil exposure. (notice Avanafil, Interactions médicamenteuses)

  • PapavérinevasodilatateurModérée

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (notice Avanafil, Mises en garde et précautions)

  • Périndoprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • PhénoxybenzaminealphabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • PhentolaminealphabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • PhényléphrinedécongestionnantModérée

    Antagonistic Effects (decrease in BIORPHEN blood pressure effect) can occur with α-adrenergic antagonists, phosphodiesterase Type 5 inhibitors, mixed α- and β-receptor antagonists, calcium channel blockers, benzodiazepines and ACE inhibitors, centrally acting sympatholytic agents. (notice Phényléphrine, Interactions médicamenteuses)

  • PindololbêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • PrazosinealphabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • PropranololbêtabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Quinaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Quinapril et hydrochlorothiazideinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Ramiprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • RifapentineantibiotiqueModérée

    …Contraceptives/Progestins Ethinyl estradiol, levonorgestrel Immunosuppressants Cyclosporine, tacrolimus Methylxanthines Theophylline Narcotic analgesics Methadone Phosphodiesterase-5 (PDE-5) Inhibitors Sildenafil Thyroid preparations Levothyroxine Tricyclic antidepressants Amitriptyline, nortriptyline 7.5 Other Interactions The conversion of PRIFTIN to 25-desacetyl… (notice Rifapentine, Interactions médicamenteuses)

  • Sacubitril et valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • SaproptérineModérée

    Drugs Affecting Nitric Oxide‑Mediated Vasorelaxation (e.g., PDE-5 inhibitors) : Potential for vasorelaxation; monitor blood pressure. (notice Saproptérine, Interactions médicamenteuses)

  • SépiaptérineModérée

    Drugs Affecting Nitric Oxide-Mediated Vasorelaxation : Potential for vasorelaxation; monitor blood pressure (e.g., PDE-5 inhibitors). (notice Sépiaptérine, Interactions médicamenteuses)

  • Sildénafilinhibiteur de la PDE5Modérée

    Prolonged Erection Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors. (notice Avanafil, Mises en garde et précautions)

  • SilodosinealphabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Sous-citrate de bismuth, métronidazole et tétracyclineantibiotiqueModérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

  • Spironolactoneantagoniste de l'aldostéroneModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Spironolactone et hydrochlorothiazideantagoniste de l'aldostéroneModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Sulfaméthoxazole et triméthoprimesulfamideModérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

  • Tadalafilinhibiteur de la PDE5Modérée

    Prolonged Erection Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors. (notice Avanafil, Mises en garde et précautions)

  • TamsulosinealphabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Telmisartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Telmisartan et amlodipineantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    CYP3A4 Substrate When administered with avanafil 200 mg, amlodipine (5 mg daily) increased the C max and AUC of avanafil by approximately 22% and 70%, respectively. (notice Avanafil, Interactions médicamenteuses)

  • Telmisartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • TérazosinealphabloquantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • TizanidinemyorelaxantModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Torasémidediurétique de l'anseModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Trandolaprilinhibiteur de l'enzyme de conversion (IEC)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Tréprostinilanalogue de prostaglandineModérée

    When vasodilators are used in combination, an additive effect on blood pressure may be anticipated. (notice Avanafil, Mises en garde et précautions)

  • Triamtérènediurétique épargneur de potassiumModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Triamtérène et hydrochlorothiazidediurétique épargneur de potassiumModérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • TriméthoprimeantibiotiqueModérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

  • Valsartanantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Valsartan et hydrochlorothiazideantagoniste des récepteurs de l'angiotensine II (ARA II)Modérée

    • Use of avanafil with alpha-blockers, other antihypertensives, or substantial amounts of alcohol (greater than 3 units) may lead to hypotension ( 2.3 , 5.6 , 5.7 ) (notice Avanafil, Mises en garde et précautions)

  • Vardénafilinhibiteur de la PDE5Modérée

    Prolonged Erection Prolonged erection greater than 4 hours and priapism (painful erections greater than 6 hours in duration) have been reported with other PDE5 inhibitors. (notice Avanafil, Mises en garde et précautions)

  • Zafirlukastantagoniste des récepteurs des leucotriènesModérée

    HIV Protease inhibitor — Ritonavir (600 mg twice daily), a strong CYP3A4 inhibitor, which also inhibits CYP2C9, increased avanafil 50 mg single-dose C max and AUC equal to approximately 2-fold and 13-fold, and prolonged the half-life of avanafil to approximately 9 hours in healthy volunteers. (notice Avanafil, Interactions médicamenteuses)

Vérifiez Avanafil avec tout ce que vous prenez. Ajoutez votre liste complète ; toutes les paires sont vérifiées en une fois.

Ouvrir dans le vérificateur

Ceci n'est pas un avis médical. Le niveau de gravité reflète la formulation de la notice, pas votre situation. Une alerte « majeure » peut être courante sous surveillance et une alerte « mineure » peut compter à forte dose. Demandez conseil à un pharmacien.